F. I. Proctor Foundation, University of California at San Francisco, San Francisco, California, USA.
Ocul Immunol Inflamm. 2010 Jun;18(3):218-22. doi: 10.3109/09273941003739910.
To report treatment results with infliximab in 2 pediatric Vogt-Koyanagi-Harada syndrome (VKH) patients.
Interventional case series.
Medical records of 2 patients were reviewed.
In 1 case with bilateral complete serous detachments, there was improvement but persistent fluid after 2 months of high-dose prednisone, methotrexate, and infliximab therapy. Infliximab was discontinued, and cyclophosphamide monthly intravenous injections were initiated with resolution of all subretinal fluid within 3 weeks. The second patient had mild subretinal fluid around the right optic nerve head tracking into the macula. Treatment with prednisone, methotrexate, and infliximab was initiated, with resolution of the subretinal fluid. Prednisone was tapered off within 4 months, and the inflammation remains controlled.
Infliximab as adjunctive therapy in pediatric VKH showed a benefit in reducing systemic corticosteroid exposure in 1 patient, but incomplete timely resolution of inflammation in another patient.
报告英夫利昔单抗治疗 2 例儿科 Vogt-Koyanagi-Harada 综合征（VKH）患者的疗效。
介入性病例系列研究。
回顾了 2 例患者的病历。
1 例双侧完全浆液性脱离患者，大剂量泼尼松龙、甲氨蝶呤和英夫利昔单抗治疗 2 个月后仍有改善，但仍有液体残留。停用英夫利昔单抗后，开始每月静脉注射环磷酰胺，3 周内所有视网膜下液均消失。第 2 例患者右眼视盘周围有轻度视网膜下液，向黄斑区延伸。开始使用泼尼松龙、甲氨蝶呤和英夫利昔单抗治疗，视网膜下液消失。4 个月内逐渐减少泼尼松龙用量，炎症仍得到控制。
英夫利昔单抗作为儿科 VKH 的辅助治疗，在 1 例患者中减少了全身皮质类固醇的暴露，而在另 1 例患者中炎症不完全及时消退。
